Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials.
Level 1 - systematic review of randomized trials
Meta-analysis of randomized controlled trials
PubMed 38373008 · doi:10.1093/cvr/cvae034
What was done
A systematic review and meta-analysis conducted according to PRISMA guidelines searched databases up to July 2023. Included studies were Phase II, III, or IV randomized controlled trials (RCTs) comparing lipid-lowering drugs against placebo with an intervention duration greater than 3 weeks and at least 100 participants per group. The primary outcome was between-group absolute mean differences (mg/L) and 95% confidence intervals (CIs) in C-reactive protein (CRP), analyzed by drug class. Meta-regression evaluated associations between CRP changes and changes in LDL cholesterol (LDL-C) or triglycerides. A total of 53 RCTs comprising 171,668 participants were included.
What was found
CRP levels (mg/L) decreased significantly with statins [-0.65 (-0.87 to -0.43)], bempedoic acid [-0.43 (-0.67 to -0.20)], ezetimibe [-0.28 (-0.48 to -0.08)], and omega-3 fatty acids [-0.27 (-0.52 to -0.01)]. Fibrates produced a non-significant reduction [-0.40 (-1.17 to 0.38)]. A slight increase in CRP was observed for PCSK9 inhibitors [0.11 (0.07 to 0.14)] and CETP inhibitors [0.10 (0.00 to 0.21), not statistically significant]. Meta-regression showed no significant correlation between CRP changes and reductions in LDL-C or triglycerides.
Why it matters
These findings establish that anti-inflammatory effects vary substantially across lipid-lowering drug classes and occur independently of LDL-C or triglyceride lowering, distinguishing therapies like statins and bempedoic acid from PCSK9 inhibitors regarding systemic inflammation.
Limits
The abstract does not report between-study heterogeneity, background cardiovascular risk profiles, or specific drug dosages. Trials with fewer than 100 participants per group, durations under 3 weeks, and non-English studies were excluded, and whether the observed CRP differences translate directly into reduced cardiovascular events requires further study.
Cited by
- supports Statins reduce C-reactive protein levels by roughly 17%.